Previous Close | 6.11 |
Open | 5.94 |
Bid | 6.35 x 3000 |
Ask | 6.45 x 900 |
Day's Range | 5.86 - 6.12 |
52 Week Range | 4.90 - 131.97 |
Volume | |
Avg. Volume | 1,949,454 |
Market Cap | 310.304M |
Beta (5Y Monthly) | 1.91 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.34 |
Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.10 |
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...